BLC2001 (NCT02365597) is often a multicenter, open up-label Phase two research analyzing the efficacy and protection of erdafitinib during the treatment of Grownup patients with regionally advanced or metastatic urothelial cancer, whose tumors have certain FGFR alterations. Ninety-nine patients were treated with an optimized dosing timetable utilizing pharmacodynamically guided dose https://johnd926uzf6.wikiexpression.com/user